Postdoctoral Fellow: Leukemia Immunology & Metabolism (ERC LIFE)

Academic Positions; Schweiz; On-site; CHF 85,000 - 110,000; Full time

Benefits offered by this job

State-of-the-art facilities

International collaboration

Mentorship programs

Job summary

Join the Blood Cancer Biology and Immunotherapy group at the University of Basel, a joint venture with University Hospitals Basel. We seek a highly motivated postdoctoral researcher (100%) to study how cellular metabolism shapes leukemia persistence, immune evasion, and anti-leukemia immunity within ERC LIFE project LIFE - Targeting bioactive lipids to overcome leukemia immune evasion and improve stem cell transplantation outcomes.

Start date is 1 February 2027 or upon agreement.

Qualifications

• PhD (or equivalent) in cancer biology, immunology, molecular biology, hematology, or a related discipline.
• Strong conceptual and experimental background in tumor biology and/or immunology.
• Substantial hands-on experience with in vivo mouse tumor models, ideally in hematological cancers.
• Extensive experience with (spectral) flow cytometry and molecular biology.

Responsibilities

• Design, perform, and interpret mechanistic experiments, including in vivo animal studies.
• Establishing and adapting experimental approaches as required.
• Analyzing and presenting scientific data.
• Mentoring PhD and MSc students.
• Contributing to manuscripts, scientific meetings, and grant applications.

Skills

English communication

Team collaboration

Scientific curiosity

Education

PhD in cancer biology/immunology

Tools

Spectral flow cytometry

In vivo mouse tumor models

CRISPR screens

Molecular biology techniques

Job description

Join the Blood Cancer Biology and Immunotherapy group at the University of Basel, a joint venture with University Hospitals Basel. We seek a highly motivated postdoctoral researcher (100%) to study how cellular metabolism shapes leukemia persistence, immune evasion, and anti-leukemia immunity within ERC LIFE project LIFE - Targeting bioactive lipids to overcome leukemia immune evasion and improve stem cell transplantation outcomes.

Start date is 1 February 2027 or upon agreement.